Pharming Group (NASDAQ:PHAR – Get Free Report) saw a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 2,800 shares, a decrease of 47.2% from the February 13th total of 5,300 shares. Based on an average trading volume of 7,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the shares of the company are sold short.
Analyst Upgrades and Downgrades
PHAR has been the topic of several research reports. Jefferies Financial Group started coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th.
Check Out Our Latest Stock Report on Pharming Group
Pharming Group Price Performance
Pharming Group (NASDAQ:PHAR – Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Sell-side analysts anticipate that Pharming Group will post -0.2 earnings per share for the current year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR – Free Report) by 16.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
- Five stocks we like better than Pharming Group
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- What is Forex and How Does it Work?
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- How to Invest in Blue Chip Stocks
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.